Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David B Clemow

Showing results (11-20 of 27) with videos related to

Pageof 3
Sort By:
Neuropsychiatric Disease and Treatment|February 23, 2017
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbiditiesDavid B Clemow, Chris Bushe, Michele Mancini, et al.
Plos One|August 23, 2014
Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled studyLenard A Adler, David B Clemow, David W Williams, et al.
CNS Neuroscience & Therapeutics|September 3, 2015
Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity DisorderSamaneh Kabul, Carlos Alatorre, Leslie B Montejano, et al.
Postgraduate Medicine|March 18, 2021
Effect of a change in lasmiditan dose on efficacy and safety in patients with migraineDavid B Clemow, Helen M Hochstetler, Yan Dong, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Medicines in Pregnancy Forum: Proceedings on Ethical and Legal ConsiderationsDavid B Clemow, Martha R Nolan, Debra L Michaels, et al.
CNS Neuroscience & Therapeutics|February 29, 2016
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized TrialsLinda A Wietecha, David B Clemow, Andrew S Buchanan, et al.
The Journal of Headache and Pain|June 12, 2020
Lasmiditan mechanism of action - review of a selective 5-HT<sub>1F</sub> agonistDavid B Clemow, Kirk W Johnson, Helen M Hochstetler, et al.
Crohn'S & Colitis 360|February 13, 2023
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease RemissionMarla C Dubinsky, David B Clemow, Theresa Hunter Gibble, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
A Proposed Framework to Address Needs of Clinical Data for Informed Medication Use in PregnancyDavid B Clemow, Lode Dewulf, Debra L Michaels, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
Clinical Data for Informed Medication Use in Pregnancy: Strengths, Limitations, Gaps, and a Need to Continue Moving ForwardDavid B Clemow, Lode Dewulf, Gideon Koren, et al.
Pageof 3

Showing results (11-20 of 27) with videos related to

Sort By:
Pageof 3
Neuropsychiatric Disease and Treatment|February 23, 2017
A review of the efficacy of atomoxetine in the treatment of attention-deficit hyperactivity disorder in children and adult patients with common comorbiditiesDavid B Clemow, Chris Bushe, Michele Mancini, et al.
Plos One|August 23, 2014
Atomoxetine effects on executive function as measured by the BRIEF--a in young adults with ADHD: a randomized, double-blind, placebo-controlled studyLenard A Adler, David B Clemow, David W Williams, et al.
CNS Neuroscience & Therapeutics|September 3, 2015
Real-World Dosing Patterns of Atomoxetine in Adults with Attention-Deficit/Hyperactivity DisorderSamaneh Kabul, Carlos Alatorre, Leslie B Montejano, et al.
Postgraduate Medicine|March 18, 2021
Effect of a change in lasmiditan dose on efficacy and safety in patients with migraineDavid B Clemow, Helen M Hochstetler, Yan Dong, et al.
Therapeutic Innovation & Regulatory Science|September 18, 2018
Medicines in Pregnancy Forum: Proceedings on Ethical and Legal ConsiderationsDavid B Clemow, Martha R Nolan, Debra L Michaels, et al.
CNS Neuroscience & Therapeutics|February 29, 2016
Atomoxetine Increased Effect over Time in Adults with Attention-Deficit/Hyperactivity Disorder Treated for up to 6 Months: Pooled Analysis of Two Double-Blind, Placebo-Controlled, Randomized TrialsLinda A Wietecha, David B Clemow, Andrew S Buchanan, et al.
The Journal of Headache and Pain|June 12, 2020
Lasmiditan mechanism of action - review of a selective 5-HT<sub>1F</sub> agonistDavid B Clemow, Kirk W Johnson, Helen M Hochstetler, et al.
Crohn'S & Colitis 360|February 13, 2023
Clinical Effect of Mirikizumab Treatment on Bowel Urgency in Patients with Moderately to Severely Active Ulcerative Colitis and the Clinical Relevance of Bowel Urgency Improvement for Disease RemissionMarla C Dubinsky, David B Clemow, Theresa Hunter Gibble, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
A Proposed Framework to Address Needs of Clinical Data for Informed Medication Use in PregnancyDavid B Clemow, Lode Dewulf, Debra L Michaels, et al.
Therapeutic Innovation & Regulatory Science|September 20, 2018
Clinical Data for Informed Medication Use in Pregnancy: Strengths, Limitations, Gaps, and a Need to Continue Moving ForwardDavid B Clemow, Lode Dewulf, Gideon Koren, et al.
Pageof 3